SE5 - PDFSEARCH.IO - Document Search Engine

SE5
Results: 40

#	Item
21	BPCA Summary of NDA[removed]SE5-017 Pediatric Supplement NDA[removed]SE5-017 Submission Date: October 14, 2002 Add to Reading List Source URL: www.fda.gov Language: English - Date: 2004-06-08 09:30:58 Cyclopropanes Otologicals Moxifloxacin Ciprofloxacin Quinolone Pefloxacin Conjunctivitis Ofloxacin Adverse effects of fluoroquinolones Piperazines Chemistry Organic chemistry
22	CLINICAL PHARMACOLOGY REVIEW NDA: [removed]SE5 022 & Submission Date(s): December 21, 2007 Brand Name Add to Reading List Source URL: www.fda.gov Language: English Carbamates Cyclopropanes Non-nucleoside reverse transcriptase inhibitors Fixed dose combination Lopinavir Efavirenz Antiretroviral drug Nevirapine Ritonavir Chemistry Organic chemistry Protease inhibitors
23	CLINICAL REVIEW Application Type[removed]Submission Number 022 Submission Code SE5 Add to Reading List Source URL: www.fda.gov Language: English Lopinavir/ritonavir Lopinavir Darunavir Antiretroviral drug Fixed-dose combination Tipranavir Atazanavir Ritonavir Efavirenz Chemistry Organic chemistry Protease inhibitors
24	CLINICAL REVIEW Application Type sNDA Submission Number[removed]S-016 Submission Code SE5 Add to Reading List Source URL: www.fda.gov Language: English Anatomy Zoledronic acid Bisphosphonate Alendronic acid Osteoporosis Osteonecrosis of the jaw Pamidronic acid Multiple myeloma Osteogenesis imperfecta Bisphosphonates Medicine Health
25	Your 5 Steps to U.S. Study EducationUSA \| Sample Undergraduate Recommendation Letter 1 Add to Reading List Source URL: www.educationusa.info Language: English - Date: 2012-10-16 04:10:28 SE5 Television Sacred Heart school EducationUSA Abigail
26	CLINICAL PHARMACOLOGY REVIEW NDA: [removed]SE5 027 &[removed]SE5 017 Submission Date(s): December 20, 2007 Brand Name Add to Reading List Source URL: www.fda.gov Language: English Non-nucleoside reverse transcriptase inhibitors Amines Drug rehabilitation Lactams Nevirapine Methadone Chemistry Organic chemistry Cyclopropanes
27	REVIEW AND EVALUATION OF CLINCIAL DATA NDA[removed]SE5-016 Sponsor: Forest Labs Drug: Celexa. (citalopram hydrocloride) Material Submitted: Pediatric Supplement SE5-016 Add to Reading List Source URL: www.fda.gov Language: English - Date: 2006-11-13 08:05:26 Organofluorides Clinical research Pharmacology Nitriles Citalopram Escitalopram Placebo-controlled study Placebo Enantiomer Chemistry Organic chemistry Selective serotonin reuptake inhibitors
28	CLINICAL PHARMACOLOGY REVIEW NDA: [removed]SE5-003 Add to Reading List Source URL: www.fda.gov Language: English Science Glucocorticoids Anxiety Bioethics Pharmacology Cortisol Mometasone furoate Placebo Melbourne Cricket Ground Medicine Health Stress
29	CLINICAL REVIEW Application Type NDA Submission Number[removed]Submission Code SE5 015 Add to Reading List Source URL: www.fda.gov Language: English Teratogens Medicine Pharmacology Clinical research Eli Lilly and Company Valproate semisodium Migraine Valproic acid Clinical trial Chemistry Anticonvulsants Mood stabilizers
30	CLINICAL REVIEW Application Type sNDA[removed]Submission Number 018 Submission Code SE5 Letter Date 10 November 2005 Add to Reading List Source URL: www.fda.gov Language: English - Date: 2007-04-09 13:27:50 Pharmacology Octreotide Peptides Design of experiments Neuroendocrine tumor Growth hormone Clinical trial Placebo Acromegaly Medicine Health Clinical research

UPDATE